Neither Neoadjuvant nor Adjuvant Therapy Increases Survival After Biliary Tract Cancer Resection with Wide Negative Margins

LAUR Repository

Show simple item record

dc.contributor.author Glazer, Evan
dc.contributor.author Lui, Ping
dc.contributor.author Abdalla, Eddie
dc.contributor.author Vauthey, Jean-Nicolas
dc.contributor.author Curley, Steven
dc.date.accessioned 2015-11-20T07:53:26Z
dc.date.available 2015-11-20T07:53:26Z
dc.date.copyright 2012
dc.date.issued 2015-11-20
dc.identifier.issn 1091-255X en_US
dc.identifier.uri http://hdl.handle.net/10725/2640
dc.description.abstract Background We investigated the role of neoadjuvant/adjuvant therapies on survival for resectable biliary tract cancer. We hypothesized that neoadjuvant and adjuvant therapy should improve the survival probability in these patients. Methods This was a retrospective review of a prospective database of patients resected for gallbladder cancer (GBC) and cholangiocarcinoma (CC). One hundred fifty-seven patients underwent resection for primary GBC (n = 63) and CC (n = 94). Fisher’s exact test, Student’s t test, the log-rank test, and a Cox proportional hazard model determined significant differences. Results The 5-year overall survival rate after resection of GBC and CC was 50.6 % and 30.4 %, respectively. Of the patients, 17.8 % received neoadjuvant chemotherapy, 48.7 % received adjuvant chemotherapy, while 15.8 % received adjuvant chemoradiotherapy. Patients with negative margins of at least 1 cm had a 5-year survival rate of 52.4 % (p < 0.01). Adjuvant therapy did not significantly prolong survival. Neoadjuvant therapy delayed surgical resection on average for 6.8 months (p < 0.0001). Immediate resection increased median survival from 42.3 to 53.5 months (p = 0.01). Conclusions Early surgical resection of biliary tract malignancies with 1 cm tumor-free margins provides the best probability for long-term survival. Currently available neoadjuvant or adjuvant therapy does not improve survival. en_US
dc.language.iso en en_US
dc.title Neither Neoadjuvant nor Adjuvant Therapy Increases Survival After Biliary Tract Cancer Resection with Wide Negative Margins en_US
dc.type Article en_US
dc.description.version Published en_US
dc.author.school SOM en_US
dc.author.idnumber 201100945 en_US
dc.author.woa N/A en_US
dc.author.department N/A en_US
dc.description.embargo N/A en_US
dc.relation.journal Journal of Gastrointestinal Surgery en_US
dc.journal.volume 16 en_US
dc.journal.issue 9 en_US
dc.article.pages 1666-1671 en_US
dc.keywords Cholangiocarcinoma en_US
dc.keywords Resection en_US
dc.keywords Neoadjuvant en_US
dc.keywords Adjuvant en_US
dc.identifier.doi http://dx.doi.org/10.1007/s11605-012-1935-1 en_US
dc.identifier.ctation Glazer, E. S., Liu, P., Abdalla, E. K., Vauthey, J. N., & Curley, S. A. (2012). Neither neoadjuvant nor adjuvant therapy increases survival after biliary tract cancer resection with wide negative margins. Journal of Gastrointestinal Surgery, 16(9), 1666-1671. en_US
dc.author.email eddie.abdalla@lau.edu.lb
dc.identifier.url http://link.springer.com/article/10.1007/s11605-012-1935-1

Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search LAUR

Advanced Search


My Account